%0 Journal Article
%T Baseline characteristics of patients enrolled in the EMPACT-MI trial.
%A Harrington J
%A Udell JA
%A Jones WS
%A Anker SD
%A Bhatt DL
%A Petrie MC
%A Andersen KR
%A Sumin M
%A Zwiener I
%A Hernandez AF
%A Butler J
%J Eur J Heart Fail
%V 25
%N 9
%D 2023 09 25
%M 37622416
%F 17.349
%R 10.1002/ejhf.2990
%X Empagliflozin has been shown to reduce the risk of adverse cardiovascular outcomes in patients with type 2 diabetes and in those with heart failure. The impact of empagliflozin in post-acute myocardial infarction (AMI) patients is unknown.<BR>The Study to Test the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction (EMPACT-MI) trial screened 6610 participants with AMI and randomized 6522 to empagliflozin or placebo in addition to standard of care. The median (interquartile) age was 64 (56-71) years and 75.1% of patients were male. Major comorbidities included hypertension (69.1%), type 2 diabetes (31.7%), prior myocardial infarction (13.0%), and atrial fibrillation (10.9%). The majority (74.3%) of patients presented with an ST-elevation myocardial infarction. Overall, 56.9% of patients had acute signs or symptoms of congestion requiring treatment and 78.3% had left ventricular systolic dysfunction with ejection fraction <45%. Clinical characteristics, including baseline demographics, rates of revascularization, and cardiovascular medications at discharge were largely comparable to recent trials of the post-AMI population.<BR>The EMPACT-MI trial will establish the benefit and risks of empagliflozin treatment in patients with AMI.